OncoMatch/Clinical Trials/NCT07106814
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Is NCT07106814 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Metabolically Armed TIL cells for advanced solid tumors.
Treatment: Metabolically Armed TIL cells — A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage IV, PERSISTENT, III, BARCELONA CLINIC LIVER CANCER (BCLC) STAGE C, BARCELONA CLINIC LIVER CANCER (BCLC) STAGE B UNSUITABLE FOR LOCAL THERAPY OR PROGRESSED AFTER LOCAL THERAPY (FIGO 2018 (cervical), BCLC (liver))
Excluded: Stage EARLY-STAGE CERVICAL CANCER (UNLESS CRITERIA ARE RELAXED IN FUTURE)
Stage Ⅳ cervical cancer according to the International Federation of Gynecology and Obstetrics (FIGO 2018) staging criteria; BCLC Stage C or Stage B unsuitable for local therapy or progressed after local therapy; advanced solid tumors
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC ≥1x10^9/L; PLT ≥80 × 10^9/L; Hb ≥90.0 g/L; no transfusions, platelet infusions, or growth factor support (except recombinant erythropoietin) within 7 days prior to enrollment
Kidney function
Estimated creatinine clearance ≥40 mL/min (Cockcroft-Gault formula)
Liver function
ALT ≤3 × ULN; AST ≤3 × ULN; TBIL ≤2 mg/dL (≤3 mg/dL for Gilbert-Meulengracht syndrome); AST and ALT ≤5 × ULN (subjects with liver metastasis); Child-Pugh score ≤7
Cardiac function
LVEF ≥45% by echocardiography or MUGA scan, with hemodynamic stability
Adequate organ function: Hematological (no transfusions, platelet infusions, or growth factor support [except recombinant erythropoietin] within 7 days prior to enrollment): ANC≥1x10^9/L; PLT ≥80 × 10^9/L; Hb ≥90.0 g/L; Blood chemistry: Estimated creatinine clearance ≥40 mL/min (Cockcroft-Gault formula); ALT ≤3 × ULN; AST ≤3 × ULN; TBIL ≤2 mg/dL (≤3 mg/dL for Gilbert-Meulengracht syndrome); AST and ALT ≤5 × ULN (subjects with liver metastasis); Child-Pugh score ≤7; Adequate pulmonary reserve defined as ≤Grade 1 dyspnea and oxygen saturation >91% on room air; LVEF ≥45% by echocardiography or MUGA scan, with hemodynamic stability
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify